Market revenue in 2023 | USD 229.4 million |
Market revenue in 2030 | USD 466.9 million |
Growth rate | 10.7% (CAGR from 2023 to 2030) |
Largest segment | Mammalian source |
Fastest growing segment | Mammalian Source |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Microbial Source, Mammalian Source, Other Source |
Key market players worldwide | WuXi Biologics (Cayman) Inc, FUJIFILM Holdings Corp, AGC Biologics, Thermo Fisher Scientific Inc, Curia, Genscript Biotech Corp Class H, Boehringer Ingelheim Pharma, Abzena, JSR Corp, Bionova Scientific |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biologics contract development market will help companies and investors design strategic landscapes.
Mammalian source was the largest segment with a revenue share of 54.8% in 2023. Horizon Databook has segmented the Japan biologics contract development market based on microbial source, mammalian source, other source covering the revenue growth of each sub-segment from 2018 to 2030.
In Japan, more than 20%of population is above 65 years of age. Hence, repairing & replacing damaged organs with stem cells and developing cost-efficient medicines are the main objectives of health care. Japan is an attractive market for outsourcing for developed nations, such as the U.S.
The regulatory process is also simpler and leads to faster clinical trial approval. For instance, clinical trials can be started once the probable benefits are demonstrated by carrying out relatively smaller number of trials.
Due to previous stringent drug registration rules, the Japanese population has been unable to access 25% of the world’s newest and most advanced drugs. To counter this, various revisions were made in the Pharmaceutical Affairs Law.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan biologics contract development market, including forecasts for subscribers. This country databook contains high-level insights into Japan biologics contract development market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account